| Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines JH Kang, JA Bluestone, A Young Trends in Immunology 42 (4), 293-311, 2021 | 88 | 2021 |
| Modulating Treg stability to improve cancer immunotherapy JH Kang, R Zappasodi Trends in cancer 9 (11), 911-927, 2023 | 47 | 2023 |
| Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor–Induced Hypophysitis Z Quandt, S Kim, J Villanueva-Meyer, C Coupe, A Young, JH Kang, ... Journal of the Endocrine Society 7 (4), bvad012, 2023 | 12 | 2023 |
| Abstract PR07: Developing syngeneic NOD tumor models to profile immunotoxicity and antitumor immunity in response to cancer immunotherapies in autoimmune-prone mice A Young, V Nguyen, JH Kang, S Mehdizadeh, A Mei, KCF Sheehan, ... Cancer Immunology Research 7 (2_Supplement), PR07-PR07, 2019 | 2 | 2019 |
| 1359 A tumor metabolism-angiogenesis-immune axis impacts the response to cancer immunotherapy I Serganova, G Colombo, JH Kang, F Ballesio, PF Gherardini, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| 555 Anti-tumor activity of Treg-depleting therapy depending on the tumor glycolytic capacity JH Kang, I Serganova, PC Ho, A Schreier, V Stearns, R Zappasodi Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| Abstract B049: Interplay between tumor metabolism, vasculature, and T-cell infiltration in anti-tumor immunity G Colombo, JH Kang, I Serganova, R Zappasodi Cancer Immunology Research 12 (10_Supplement), B049-B049, 2024 | | 2024 |
| Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response Z Quandt, S Jacob, MZH Fadlullah, C Wu, C Wu, L Huppert, LS Levine, ... BJC reports 2 (1), 46, 2024 | | 2024 |
